ArticleAnnals of medicine2025
Trends and projections of ischemic heart disease burden in the Belt and Road countries and China from 1990 to 2021: a study based on the 2021 global burden of disease.
Article in Annals of medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Three decades of global ischemic heart disease burden: Trends, disparities, and drivers from 1990 to 2021.Medicine · 2026Article
- A comprehensive review of ischemic heart disease: pathophysiology, current treatments, natural products-based therapies, and nanotherapeutics.Frontiers in pharmacology · 2026Review
- Physical activity and myocardial infarction risk: insights from the global burden of disease study 1990-2021 and Mendelian randomization analysis.BMC cardiovascular disorders · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo assess the burden of ischemic heart disease (IHD) in Belt and Road Initiative countries from 1990 to 2021 and to predict future trends.
methodsUtilizing data from GBD 2021, we analyzed incidence, mortality, and other indicators using Joinpoint analysis, NetDrift methodology, age-period-cohort models, and Bayesian Age-Period-Cohort (BAPC) predictive modeling.
resultsIn 2021, China bore the heaviest IHD burden with an incidence of 7.3 million cases and a mortality rate of 1.96 million. The United Arab Emirates experienced over a tenfold increase in incidence/prevalence rates, while Djibouti saw a fivefold rise in deaths/DALYs. Uzbekistan's standardized incidence rate increased by 107.2%, and Lesotho's mortality rate rose by 78.7%. A higher proportion of affected individuals were male or aged over 60 years; aging populations and demographic growth emerged as primary driving factors. Low/medium-low SDI regions exhibited significant potential for improvement; emerging risks included renal insufficiency and low grain diets. Projections indicate that by 2046, the number of IHD cases in China may exceed 14,410,378 individuals, highlighting a severe prevention and control challenge.
conclusionThe burden of IHD demonstrates regional disparities characterized by the interplay between traditional risk factors and emerging threats. It is recommended to establish a stratified governance framework that enhances cross-national data sharing and facilitates the transfer of digital health technologies to optimize cardiovascular disease prevention strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.